Logo image of REGN

REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis

NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD

564.64  -7.75 (-1.35%)

After market: 511.892 -52.75 (-9.34%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to REGN. REGN was compared to 556 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make REGN suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year REGN was profitable.
In the past year REGN had a positive cash flow from operations.
REGN had positive earnings in each of the past 5 years.
Each year in the past 5 years REGN had a positive operating cash flow.
REGN Yearly Net Income VS EBIT VS OCF VS FCFREGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

REGN has a better Return On Assets (11.98%) than 95.32% of its industry peers.
REGN's Return On Equity of 15.31% is amongst the best of the industry. REGN outperforms 95.50% of its industry peers.
REGN has a better Return On Invested Capital (9.45%) than 94.96% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for REGN is below the industry average of 14.97%.
Industry RankSector Rank
ROA 11.98%
ROE 15.31%
ROIC 9.45%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
REGN Yearly ROA, ROE, ROICREGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

With an excellent Profit Margin value of 31.94%, REGN belongs to the best of the industry, outperforming 97.12% of the companies in the same industry.
REGN's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 28.85%, REGN belongs to the best of the industry, outperforming 97.48% of the companies in the same industry.
REGN's Operating Margin has been stable in the last couple of years.
With an excellent Gross Margin value of 86.69%, REGN belongs to the best of the industry, outperforming 89.93% of the companies in the same industry.
REGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.85%
PM (TTM) 31.94%
GM 86.69%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
REGN Yearly Profit, Operating, Gross MarginsREGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
The number of shares outstanding for REGN has been reduced compared to 5 years ago.
Compared to 1 year ago, REGN has an improved debt to assets ratio.
REGN Yearly Shares OutstandingREGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
REGN Yearly Total Debt VS Total AssetsREGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

An Altman-Z score of 6.93 indicates that REGN is not in any danger for bankruptcy at the moment.
REGN has a better Altman-Z score (6.93) than 80.58% of its industry peers.
The Debt to FCF ratio of REGN is 0.91, which is an excellent value as it means it would take REGN, only 0.91 years of fcf income to pay off all of its debts.
REGN has a Debt to FCF ratio of 0.91. This is amongst the best in the industry. REGN outperforms 95.32% of its industry peers.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
REGN has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: REGN underperforms 64.75% of its industry peers.
Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.91
Altman-Z 6.93
ROIC/WACC0.99
WACC9.57%
REGN Yearly LT Debt VS Equity VS FCFREGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

A Current Ratio of 4.93 indicates that REGN has no problem at all paying its short term obligations.
The Current ratio of REGN (4.93) is comparable to the rest of the industry.
REGN has a Quick Ratio of 4.03. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN's Quick ratio of 4.03 is in line compared to the rest of the industry. REGN outperforms 48.02% of its industry peers.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 4.03
REGN Yearly Current Assets VS Current LiabilitesREGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.47% over the past year.
Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 7.52%.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%

3.2 Future

The Earnings Per Share is expected to grow by 5.56% on average over the next years.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 4.44% on average per year.
EPS Next Y-20.91%
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
EPS Next 5Y5.56%
Revenue Next Year-5.47%
Revenue Next 2Y0.46%
Revenue Next 3Y3.8%
Revenue Next 5Y4.44%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
REGN Yearly Revenue VS EstimatesREGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B
REGN Yearly EPS VS EstimatesREGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.74, which indicates a correct valuation of REGN.
Based on the Price/Earnings ratio, REGN is valued cheaply inside the industry as 96.40% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.35, REGN is valued rather cheaply.
With a Price/Forward Earnings ratio of 14.02, REGN is valued correctly.
94.60% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
REGN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.54.
Industry RankSector Rank
PE 12.74
Fwd PE 14.02
REGN Price Earnings VS Forward Price EarningsREGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

96.76% of the companies in the same industry are more expensive than REGN, based on the Enterprise Value to EBITDA ratio.
94.42% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.58
EV/EBITDA 11.16
REGN Per share dataREGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.97
EPS Next 2Y-6.05%
EPS Next 3Y2.71%

More info and screens

2

5. Dividend

5.1 Amount

REGN has a yearly dividend return of 0.64%, which is pretty low.
Compared to an average industry Dividend Yield of 93.30, REGN pays a better dividend. On top of this REGN pays more dividend than 98.38% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.64%

5.2 History

REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
REGN Yearly Dividends per shareREGN Yearly Dividends per shareYearly Dividends per share 2025 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
REGN Yearly Income VS Free CF VS DividendREGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

REGENERON PHARMACEUTICALS

NASDAQ:REGN (7/24/2025, 6:38:35 PM)

After market: 511.892 -52.75 (-9.34%)

564.64

-7.75 (-1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)08-01 2025-08-01/bmo
Inst Owners92.08%
Inst Owner Change-0.71%
Ins Owners1.86%
Ins Owner Change0%
Market Cap60.96B
Analysts79.41
Price Target751.62 (33.11%)
Short Float %2.17%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield 0.64%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date05-20 2025-05-20 (0.88)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-8.66%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)1.88%
Min EPS beat(4)-8.66%
Max EPS beat(4)6.79%
EPS beat(8)6
Avg EPS beat(8)2.08%
EPS beat(12)10
Avg EPS beat(12)5.54%
EPS beat(16)13
Avg EPS beat(16)9.63%
Revenue beat(2)0
Avg Revenue beat(2)-5.11%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)-0.91%
Revenue beat(4)1
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)2.93%
Revenue beat(8)4
Avg Revenue beat(8)-0.63%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)12
Avg Revenue beat(16)4.32%
PT rev (1m)-4.53%
PT rev (3m)-21.09%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)-18.35%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-14.17%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-7.96%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-7.65%
Valuation
Industry RankSector Rank
PE 12.74
Fwd PE 14.02
P/S 4.33
P/FCF 20.58
P/OCF 15.42
P/B 2.07
P/tB 2.16
EV/EBITDA 11.16
EPS(TTM)44.31
EY7.85%
EPS(NY)40.28
Fwd EY7.13%
FCF(TTM)27.43
FCFY4.86%
OCF(TTM)36.61
OCFY6.48%
SpS130.46
BVpS272.18
TBVpS261.37
PEG (NY)N/A
PEG (5Y)0.97
Profitability
Industry RankSector Rank
ROA 11.98%
ROE 15.31%
ROCE 11.96%
ROIC 9.45%
ROICexc 12.53%
ROICexgc 13.12%
OM 28.85%
PM (TTM) 31.94%
GM 86.69%
FCFM 21.03%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
ROICexc(3y)40.56%
ROICexc(5y)38.47%
ROICexgc(3y)47.83%
ROICexgc(5y)42.84%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.91
Debt/EBITDA 0.59
Cap/Depr 199.98%
Cap/Sales 7.04%
Interest Coverage 250
Cash Conversion 86.71%
Profit Quality 65.83%
Current Ratio 4.93
Quick Ratio 4.03
Altman-Z 6.93
F-Score5
WACC9.57%
ROIC/WACC0.99
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)2.47%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-13.93%
EPS Next Y-20.91%
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
EPS Next 5Y5.56%
Revenue 1Y (TTM)7.52%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%-3.69%
Revenue Next Year-5.47%
Revenue Next 2Y0.46%
Revenue Next 3Y3.8%
Revenue Next 5Y4.44%
EBIT growth 1Y-0.68%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year-16.54%
EBIT Next 3Y6.1%
EBIT Next 5Y6.01%
FCF growth 1Y17.22%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-7.66%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%